A framework for interpreting genome-wide association studies of psychiatric disorders.
P Sullivan - Molecular psychiatry, 2009 - psycnet.apa.org
Molecular psychiatry, 2009•psycnet.apa.org
Genome-wide association studies (GWAS) have yielded a plethora of new findings in the
past 3 years. By early 2009, GWAS on 47 samples of subjects with attention-deficit
hyperactivity disorder, autism, bipolar disorder, major depressive disorder and
schizophrenia will be completed. Taken together, these GWAS constitute the largest
biological experiment ever conducted in psychiatry (59000 independent cases and controls,
7700 family trios and> 40 billion genotypes). We know that GWAS can work, and the …
past 3 years. By early 2009, GWAS on 47 samples of subjects with attention-deficit
hyperactivity disorder, autism, bipolar disorder, major depressive disorder and
schizophrenia will be completed. Taken together, these GWAS constitute the largest
biological experiment ever conducted in psychiatry (59000 independent cases and controls,
7700 family trios and> 40 billion genotypes). We know that GWAS can work, and the …
Abstract
Genome-wide association studies (GWAS) have yielded a plethora of new findings in the past 3 years. By early 2009, GWAS on 47 samples of subjects with attention-deficit hyperactivity disorder, autism, bipolar disorder, major depressive disorder and schizophrenia will be completed. Taken together, these GWAS constitute the largest biological experiment ever conducted in psychiatry (59000 independent cases and controls, 7700 family trios and> 40 billion genotypes). We know that GWAS can work, and the question now is whether it will work for psychiatric disorders. In this review, we describe these studies, the Psychiatric GWAS Consortium for meta-analyses of these data, and provide a logical framework for interpretation of some of the conceivable outcomes.(PsycINFO Database Record (c) 2016 APA, all rights reserved)
American Psychological Association